{
    "organizations": [],
    "uuid": "d84f80f4a8893c2a0201b5fdd5dd32719e185edc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-marinus-pharmaceuticals-reports-qu/brief-marinus-pharmaceuticals-reports-quarterly-loss-per-share-0-15-idUSASC09YYA",
    "ord_in_thread": 0,
    "title": "Marinus Pharmaceuticals Reports Quarterly Loss Per Share $0.15",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2 (Reuters) - Marinus Pharmaceuticals Inc:\n* MARINUS PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND FIRST QUARTER 2018 FINANCIAL RESULTS\n* MARINUS PHARMACEUTICALS INC QUARTERLY LOSS PER SHARE $0.15\n* MARINUS PHARMACEUTICALS INC - AT MARCH 31, 2018, HAD CASH, CASH EQUIVALENTS AND INVESTMENTS OF $52.0 MILLION, COMPARED TO $58.4 MILLION AT DECEMBER 31, 2017\n* MARINUS PHARMACEUTICALS -BELIEVES THAT ITS CASH, CASH EQUIVALENTS AND INVESTMENTS, AS OF MARCH 31, 2018, ARE ADEQUATE TO FUND ITS OPERATIONS INTO 2020 ",
    "published": "2018-05-02T19:40:00.000+03:00",
    "crawled": "2018-05-02T14:57:53.029+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "marinus",
        "pharmaceutical",
        "inc",
        "marinus",
        "pharmaceutical",
        "provides",
        "business",
        "update",
        "first",
        "quarter",
        "financial",
        "result",
        "marinus",
        "pharmaceutical",
        "inc",
        "quarterly",
        "loss",
        "per",
        "share",
        "marinus",
        "pharmaceutical",
        "inc",
        "march",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "million",
        "compared",
        "million",
        "december",
        "marinus",
        "pharmaceutical",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "march",
        "adequate",
        "fund",
        "operation"
    ]
}